{"id":"W4415940731","doi":"10.1016/j.annonc.2025.08.3688","title":"3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System","funders":"Astellas Pharma; Pfizer","keywords":"Pembrolizumab; Urothelial cancer; Cohort; Cisplatin; Metastatic Urothelial Carcinoma; Expanded access; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006618498,0.0003879296,0.0007248783,0.0001723703,0.0002335192,0.0006722067,0.0004774295,0.0004290377,0.005368205],"category_scores_gemma":[0.0007490987,0.0001998305,0.0008230566,0.0002237449,0.0003424441,0.0004342077,0.0002443302,0.001344846,0.0009668087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009830685,"about_ca_system_score_gemma":0.001179518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002292618,"about_ca_topic_score_gemma":0.003707175,"domain_scores_codex":[0.9997949,0.00006976139,0.00001141328,0.00004212371,0.00002501325,0.00005671398],"domain_scores_gemma":[0.999676,0.00005436532,0.00005616643,0.00005361452,0.00002886517,0.000131049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7188581,0.01496122,0.02932804,0.0004153883,0.00148446,0.0002436546,0.000170864,0.002618501,0.03545359,0.0004302236,0.01390259,0.1821334],"study_design_scores_gemma":[0.2656661,0.4679749,0.2098694,0.0002519406,0.002595198,0.001356156,0.0003252403,0.006890781,0.0220737,0.0009144032,0.02196482,0.0001172073],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935367,0.0005758684,0.0002010353,0.0001648841,0.00005720879,0.0002240554,0.00289421,0.00005896003,0.002287092],"genre_scores_gemma":[0.991868,0.0003453243,0.0002986627,0.0001962518,0.00003283108,0.0001888139,0.005206535,0.0000206932,0.001842867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005368205,"threshold_uncertainty_score":0.0179584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0360325907053891,"score_gpt":0.3754102315221576,"score_spread":0.3393776408167685,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}